Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2008-10-01 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2008
Regulatory Filings Classification · 94% confidence The document is a press release dated October 1, 2008, announcing that Medivir has submitted a registration application (registreringsansökan) for its product Lipsovir® to the US Food and Drug Administration (FDA). This announcement concerns a significant regulatory step related to a product's approval process, which is a key activity for a pharmaceutical company. It is not a full financial report (10-K or IR), an earnings release (ER), or a management discussion (MDA). It is a specific announcement regarding regulatory submission and clinical trial results. While it touches upon clinical data, the primary focus is the submission itself. This type of specific, material, non-financial regulatory update often falls under general Regulatory Filings (RNS) or, if it were about a legal dispute, LTR. Given the context of a major regulatory submission for a drug product, RNS is the most appropriate general regulatory category, as there isn't a specific code for 'Drug Approval Submission Announcement'. It is not a proxy statement (PSI), director dealing (DIRS), or capital change (CAP). Since it is a formal announcement of a regulatory action, RNS is the best fit among the available options, acting as a catch-all for significant, non-standard regulatory news.
2008-10-01 Swedish
Earnings Release 2008
Earnings Release Classification · 92% confidence The document is titled "Press Release" and announces that data on a drug (TMC435350) will be presented at an upcoming medical meeting (AASLD). It details the content of the abstracts accepted for presentation, including safety, antiviral activity, and pharmacokinetics, and provides specific clinical results (e.g., RVR rates). This structure—a press release summarizing clinical trial data that is about to be presented publicly—is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress. Since it is a press release announcing key clinical findings rather than a comprehensive quarterly/annual report (10-K or IR) or a transcript of a call (CT), the most appropriate classification is Earnings Release (ER), as these often include operational/clinical updates alongside financial highlights, or it could be considered a Regulatory Filing (RNS) if it's purely clinical. Given the focus on presenting data and the format of a press release summarizing results, ER is a strong fit, although it lacks explicit financial figures. However, since it is a formal announcement of results/data presentation, and not a full report, it is best classified as an Earnings Release (ER) or potentially a Regulatory Filing (RNS). Given the context of financial reporting databases, press releases summarizing key operational/clinical milestones are often grouped with ERs. I will lean towards ER as it summarizes 'results' (clinical results). The document length (5028 chars) is substantial enough to contain more than just a link, supporting classification as the announcement itself rather than just an RPA. FY 2008
2008-09-24 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a press release dated September 24, 2008, announcing that data regarding the drug TMC435350 will be presented at the AASLD conference. It details the abstracts accepted for poster presentation, which cover clinical trial results (Phase IIa study OPERA-1) and preclinical data. This is not a full Annual Report (10-K), an Interim Report (IR), or a formal Audit Report (AR). It is an announcement about upcoming presentation of scientific/clinical data, which is a common type of communication related to investor relations and clinical progress. Since it is an announcement detailing results that will be presented at a scientific meeting, it most closely aligns with an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it were summarizing financial results. However, this document is specifically announcing the presentation of clinical/scientific data at a medical conference (AASLD). Given the options, and recognizing that it is a formal announcement of scientific findings intended for stakeholders, it functions similarly to an Earnings Release (ER) by providing key results, but the core subject is the presentation of clinical data. Since it is a press release announcing key data points and abstracts for a scientific meeting, it is best classified as an Earnings Release (ER) as it communicates key performance/progress indicators, or potentially a Regulatory Filing (RNS) if no better fit exists. Given the content focuses heavily on clinical trial results and safety data, which are often highlighted in ERs or IP, and since it is a press release format, ER is a strong candidate for communicating key progress. However, if we strictly follow the definitions, it is an announcement of data presentation, not the full financial results (ER) or a formal investor presentation (IP). Since it is a press release announcing scientific/clinical progress, and not a standard financial report, RNS (Regulatory Filings - fallback) is often used for such specific announcements, but ER is often used for clinical trial updates that drive investor sentiment. Given the focus on clinical trial results (safety, efficacy, PK), it is a significant update for investors. I will lean towards ER as it communicates key performance indicators (clinical efficacy/safety) in a press release format, which is the standard vehicle for ERs. If the document were purely about the *fact* that a report was published, RPA would apply, but this document contains the substance of the findings. I will classify it as ER.
2008-09-24 Swedish
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is a 'halvårsrapport' (half-year report) for Medivir for the period 1 January – 30 June 2008. It contains comprehensive financial data, including net sales, profit/loss, earnings per share, cash flow, and liquid assets, as well as detailed management commentary on business operations, clinical trials, and partnerships. Since it covers a period shorter than a full fiscal year and includes substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. H2 2008
2008-07-09 Swedish
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Medivir, Interim Report, 1 January – 30 June 2008'. It contains comprehensive financial data, including consolidated net sales, loss after tax, earnings per share, cash flow, and liquid assets for the specified six-month period. It also includes a CEO statement, business updates, and detailed project portfolio tables. As it provides substantive financial statements and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2008
2008-07-09 English
Report Publication Announcement 2008
Report Publication Announcement Classification · 99% confidence The document is a very short press release (655 characters) dated May 20, 2008. It announces that Medivir participated in and presented at the 'Acumen BioFin Rodman & Renshaw 5th Annual Healthcare Conference'. Crucially, it states, 'The presentation is now available on Medivir's website under the Investor&Media/Latest events tab.' This structure—a brief announcement stating that presentation materials are available elsewhere—fits the definition of a Report Publication Announcement (RPA) or potentially an Investor Presentation (IP) if the content was the presentation itself. Given the context of announcing participation and directing users to the website for the presentation, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule, as this is the announcement of the material, not the material itself. However, since the material being announced is explicitly a 'presentation' given at an investor conference, IP (Investor Presentation) is also highly relevant. Since the text is an announcement *about* the presentation being available, RPA is the primary fit for the announcement wrapper, but IP describes the content being announced. Given the context of investor relations announcements about conference participation, RPA (Report Publication Announcement) is the best fit for the wrapper document itself.
2008-05-20 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.